Drilling Down on <em>FLT3</em>-Mutated Acute Myeloid Leukemia
Symposium
Symposium

Drilling Down on FLT3-Mutated Acute Myeloid Leukemia

FLT Like a Butterfly, Sting Like a Bee

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

Overexpression of or mutations in the FMS‐like tyrosine kinase 3 (FLT3) define a unique subtype of acute myeloid leukemia (AML) with poor prognosis. The current standard of care for FLT3‐mutated AML remains limited to intensive induction chemotherapy, with the potential for post‐remission chemotherapy and hematopoietic stem cell transplant in appropriate patients. Recently, targeted therapies have been investigated in the first‐line setting as an addition to the induction regimen, with FLT3‐directed inhibitors being able to improve rates of complete remission and overall survival. Numerous first-generation and second-generation FLT3 inhibitors are being evaluated within the context of clinical trials across various disease settings.

As the targeted therapy options for FLT3‐mutated AML expand, it is essential for clinicians to keep up with new developments in understanding of disease biology, as well as the findings from clinical trials investigating first‐ and second‐generation FLT3 inhibitors.

Join a group of world-renowned experts to learn the latest about the use of FLT3 inhibitors in AML and ensure that you are at the forefront of this emerging area.

This symposium is held in conjunction with the ESH 4th International Conference on Acute Myeloid Leukemia.

Date and Location

Thursday, 5 October 2017
13.05 – 14.05

Auditorium
Estoril Congress Center
Avenida Amaral
Estoril, Portugal

Date/Time

Date/Time

Thursday, 5 October 2017
13.05 – 14.05

Location

Location

Estoril, Portugal

IME

IME

13.05 Welcome and introduction
Martin Tallman, MD
13.10 Examining the scope of FLT3-mutated AML
Martin Tallman, MD
13.20 First things first: Experience with 1st generation FLT3 inhibitors
Miguel Sanz, MD
13.35 Second wave of options: 2nd generation FLT3 inhibitors
Francesco Lo-Coco, MD
13.50 Expert panel discussion
Martin Tallman, MD, Miguel Sanz, MD, Francesco Lo-Coco, MD
14.00 prIME Points™
Martin Tallman, MD
14.05 Adjourn

    Chair

  • Martin Tallman, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Faculty

  • Francesco Lo-Coco, MDUniversity Tor Vergata
    Rome, Italy
  • Miguel Sanz, MDValencia University Medical School
    University Hospital La Fe
    Valencia, Spain

This educational activity is specifically designed to meet the needs of hematologists and other healthcare professionals involved in the treatment of patients with acute myeloid leukemia.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

After successful completion of this educational activity, participants should be able to:

  • Identify the key diagnostic and prognostic features of FLT3‐mutated AML, and describe the rationale for actionable molecular targets in this disease subtype
  • Describe the differences in specificity of the FLT3 inhibitors and how this may identify when they are likely to be most beneficial (as initial therapy or in relapsed disease)
  • Assess recent clinical trial data for both first‐generation and second‐generation FLT3 inhibitors in FLT3‐mutated AML

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.